The Latest Breaking News from Cigna

Persistent economic turbulence and an uncertain outlook have led investors to prioritize steady income generation from their investments. Hence, fundamentally sound dividend yielders with a solid track record and potential for perpetual growth Merck (MRK), Abbott (ABT), Cigna (CI), Energy Transfer (ET), and Kronos (KRO) could be permanent additions to…

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 15 strange trades.

When Dani Yuengling felt a lump in her right breast last summer, she tried to ignore it.

A hospital's cost calculator said her procedure would be $1,400 for patients without insurance. Instead, the bill was almost $18,000 and, her part was more than $5,000 — the balance of her deductible.

Someone with a lot of money to spend has taken a bearish stance on Cigna (NYSE:CI). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 13 strange trades.

A whale with a lot of money to spend has taken a noticeably bearish stance on Cigna. Looking at options history for Cigna (NYSE:CI) we detected 11 strange trades.

Cigna (NYSE:CI) has outperformed the market over the past 10 years by 9.15% on an annualized basis producing an average annual return of 20.13%. Currently, Cigna has a market capitalization of $84.90 billion.

Cigna Corp (NYSE: CI) is poised to benefit from the launch of bioequivalent Humira in July 2023, according to Morgan Stanley.

Upgrades

GARP is a strategy to blend the best parts of value and growth investing. It's particularly apt as it will allow investors to identify the top growth stocks trading at attractive valuations such as Cigna (CI), Freeport McMoran (FCX), and Micron (MU).